CONTEXT: Denosumab discontinuation is characterized by an increase in bone turnover overriding pre-treatment status, a rapid bone loss in the majority and multiple vertebral fractures (VFx) in some patients. METHODS: A working group of the European Calcified Tissue Society (ECTS) performed an update...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!